9.3 HDFN Pathophysiology & Detection

9.3 HDFN Pathophysiology & Detection

Quick Answer: Hemolytic disease of the fetus and newborn (HDFN) occurs when a maternal IgG alloantibody crosses the placenta and destroys fetal red cells carrying a paternally-inherited antigen the mother lacks. Anti-D is the classic severe cause; anti-K (Kell) is uniquely severe because it also suppresses fetal erythropoiesis; ABO HDFN from anti-A/anti-B is usually mild. Detection combines maternal antibody screening and titers, fetal antigen genotyping, and middle cerebral artery Doppler studies (MCA-PSV) to identify fetal anemia before it becomes life-threatening.

Mechanism of HDFN

HDFN requires three conditions: the mother must lack a red cell antigen that the fetus carries (inherited from the father), the mother must be alloimmunized (or have naturally occurring IgG, as in ABO HDFN), and the antibody must be of an IgG subclass capable of active transport across the placenta via the neonatal Fc receptor (FcRn). IgM antibodies (such as most examples of anti-I, anti-Lea, and anti-P1) do not cross the placenta and do not cause HDFN regardless of titer. Once maternal IgG crosses into the fetal circulation, it coats antigen-positive fetal red cells, which are then removed primarily by extravascular hemolysis in the fetal spleen and liver. Sustained hemolysis drives fetal reticulocytosis and, in severe cases, extramedullary hematopoiesis, hepatosplenomegaly, hypoproteinemia, and ultimately hydrops fetalis (generalized fetal edema and effusions from severe anemia and heart failure).

Antibodies of Clinical Significance

Anti-K deserves specialist-level emphasis: because it suppresses red cell production at the progenitor level in addition to causing hemolysis, both maternal titer and amniotic fluid bilirubin (delta OD450) correlate poorly with fetal anemia severity, so management guidelines lower the critical titer threshold and, in some protocols, recommend proceeding directly to Doppler surveillance regardless of titer.

ABO HDFN vs. Rh HDFN

ABO HDFN is common (occurring in a meaningful fraction of group O mother/group A or B infant pairings) but is rarely severe, because A and B antigens are weakly expressed on fetal and neonatal red cells, are also expressed on other tissues and in secretions (which absorb and neutralize some antibody before it reaches red cells), and the fetal red cell membrane is less rigid, resisting complement-mediated damage. Clinically, ABO HDFN presents as early neonatal jaundice with a weakly positive or negative direct antiglobulin test (DAT) and spherocytes on the peripheral smear, and it rarely causes significant fetal anemia or hydrops. By contrast, unresolved Rh(D) or Kell alloimmunization can progress to severe fetal anemia and hydrops, and typically does not affect a first pregnancy (the sensitizing event) but threatens subsequent pregnancies carrying an antigen-positive fetus.

Prenatal Detection and Surveillance

Every pregnant patient receives an antibody screen (indirect antiglobulin test) at the first prenatal visit, repeated around 28 weeks for D-negative patients before RhIG administration. If a clinically significant antibody is identified, the workup proceeds as follows:

1. Determine paternal antigen status/zygosity or use cell-free fetal DNA (cffDNA) from maternal plasma to noninvasively genotype the fetus for the relevant antigen (RHD genotyping in particular has high sensitivity and specificity and avoids invasive procedures).
2. If the fetus is antigen-positive or antigen status is unknown, perform serial maternal antibody titers every 2-4 weeks.
3. Compare each titer to the laboratory's critical titer - conventionally 1:16 for most clinically significant antibodies, but a lower threshold of 1:4 for anti-K given its erythrosuppressive mechanism. A rise of more than one dilution between specimens run in parallel is considered significant.
4. Once the critical titer is reached (or immediately, regardless of titer, if there is a history of a prior affected pregnancy or a Kell antibody), begin weekly MCA-PSV Doppler surveillance, typically starting by 16-18 weeks gestation.
5. An MCA-PSV at or above 1.5 multiples of the median (MoM) for gestational age indicates a high probability of moderate-to-severe fetal anemia (sensitivity roughly 86%, specificity roughly 71%) and warrants cordocentesis (percutaneous umbilical blood sampling) to directly measure fetal hemoglobin/hematocrit before deciding on intrauterine transfusion.

Titers lose reliability once a pregnancy has already been affected by HDFN; in that setting, MCA-PSV surveillance is used directly rather than waiting for a titer threshold.

Postnatal Detection

At delivery, cord blood testing typically includes a direct antiglobulin test (DAT), ABO/Rh type, hemoglobin/hematocrit, and total bilirubin. A positive DAT confirms antibody coating of the infant's red cells; an antibody elution can recover and identify the specific antibody from the infant's cells when maternal antibody specificity was not previously known or needs confirmation. Reticulocytosis, polychromasia, and nucleated red blood cells on the peripheral smear reflect the compensatory marrow response to ongoing hemolysis and help gauge severity alongside serial bilirubin measurements.